nodes	percent_of_prediction	percent_of_DWPC	metapath
Lorazepam—Chlorthalidone—CA9—hematologic cancer	0.00161	0.213	CrCbGaD
Lorazepam—Clozapine—H1F0—hematologic cancer	0.00127	0.168	CrCbGaD
Lorazepam—Diclofenac—ALOX5—hematologic cancer	0.00121	0.16	CrCbGaD
Lorazepam—Diclofenac—UGT1A1—hematologic cancer	0.00106	0.141	CrCbGaD
Lorazepam—Midazolam—SLC22A1—hematologic cancer	0.000534	0.0705	CrCbGaD
Lorazepam—GABRB3—Ion channel transport—SGK1—hematologic cancer	0.000389	0.00599	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—RET—hematologic cancer	0.000386	0.00595	CbGpPWpGaD
Lorazepam—GABRA1—Ion channel transport—ATP1B1—hematologic cancer	0.000385	0.00593	CbGpPWpGaD
Lorazepam—GABRG2—Ion channel transport—ATP4A—hematologic cancer	0.000382	0.00588	CbGpPWpGaD
Lorazepam—GABRG2—Ion channel transport—SGK1—hematologic cancer	0.000382	0.00588	CbGpPWpGaD
Lorazepam—UGT2B15—Biological oxidations—GSTM1—hematologic cancer	0.000367	0.00565	CbGpPWpGaD
Lorazepam—GABRA1—Ion channel transport—SGK1—hematologic cancer	0.000334	0.00514	CbGpPWpGaD
Lorazepam—GABRA1—Ion channel transport—ATP4A—hematologic cancer	0.000334	0.00514	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PHYH—hematologic cancer	0.000306	0.00471	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GMPS—hematologic cancer	0.000306	0.00471	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—FTCD—hematologic cancer	0.000306	0.00471	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—ALPL—hematologic cancer	0.000292	0.00449	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—STAT5B—hematologic cancer	0.000292	0.00449	CbGpPWpGaD
Lorazepam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY7—hematologic cancer	0.00029	0.00446	CbGpPWpGaD
Lorazepam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY7—hematologic cancer	0.000285	0.00438	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—SMPD3—hematologic cancer	0.00028	0.00431	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—NCAM1—hematologic cancer	0.000276	0.00424	CbGpPWpGaD
Lorazepam—Clonazepam—ALB—hematologic cancer	0.000272	0.036	CrCbGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—RUNX3—hematologic cancer	0.000272	0.00419	CbGpPWpGaD
Lorazepam—GABRB3—Orphan transporters—CYCS—hematologic cancer	0.000267	0.00412	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—HDAC9—hematologic cancer	0.000264	0.00406	CbGpPWpGaD
Lorazepam—GABRG2—Orphan transporters—CYCS—hematologic cancer	0.000263	0.00404	CbGpPWpGaD
Lorazepam—Diclofenac—ALB—hematologic cancer	0.000261	0.0345	CrCbGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—FOXM1—hematologic cancer	0.000261	0.00402	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—EIF4EBP1—hematologic cancer	0.000259	0.00399	CbGpPWpGaD
Lorazepam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CAMK2D—hematologic cancer	0.000258	0.00397	CbGpPWpGaD
Lorazepam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CAMK2D—hematologic cancer	0.000253	0.0039	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—MYB—hematologic cancer	0.000251	0.00387	CbGpPWpGaD
Lorazepam—Diclofenac—ABCB1—hematologic cancer	0.000249	0.0329	CrCbGaD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY7—hematologic cancer	0.000249	0.00383	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—B3GAT1—hematologic cancer	0.000245	0.00377	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—DCK—hematologic cancer	0.000245	0.00377	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ASNS—hematologic cancer	0.000245	0.00377	CbGpPWpGaD
Lorazepam—GABRB3—Transmission across Chemical Synapses—SLC22A1—hematologic cancer	0.000238	0.00366	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000236	0.00363	CbGpPWpGaD
Lorazepam—GABRG2—Transmission across Chemical Synapses—SLC22A1—hematologic cancer	0.000233	0.00359	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—HDC—hematologic cancer	0.000232	0.00357	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000232	0.00357	CbGpPWpGaD
Lorazepam—GABRA1—Orphan transporters—CYCS—hematologic cancer	0.00023	0.00353	CbGpPWpGaD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CAMK2D—hematologic cancer	0.000221	0.00341	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000219	0.00338	CbGpPWpGaD
Lorazepam—GABRB3—Transmission across Chemical Synapses—ADCY7—hematologic cancer	0.000218	0.00335	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000215	0.00331	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—IL13—hematologic cancer	0.000215	0.00331	CbGpPWpGaD
Lorazepam—GABRG2—Transmission across Chemical Synapses—ADCY7—hematologic cancer	0.000214	0.00329	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CDA—hematologic cancer	0.000212	0.00327	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PC—hematologic cancer	0.000204	0.00315	CbGpPWpGaD
Lorazepam—GABRA1—Transmission across Chemical Synapses—SLC22A1—hematologic cancer	0.000204	0.00314	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000202	0.00312	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—STAT1—hematologic cancer	0.000198	0.00304	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GBA—hematologic cancer	0.000197	0.00304	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—SLC35B2—hematologic cancer	0.000197	0.00304	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—GATA3—hematologic cancer	0.000194	0.00299	CbGpPWpGaD
Lorazepam—GABRB3—Transmission across Chemical Synapses—CAMK2D—hematologic cancer	0.000194	0.00298	CbGpPWpGaD
Lorazepam—GABRG2—Transmission across Chemical Synapses—CAMK2D—hematologic cancer	0.00019	0.00293	CbGpPWpGaD
Lorazepam—Nitrazepam—ABCB1—hematologic cancer	0.000188	0.0249	CrCbGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000188	0.0029	CbGpPWpGaD
Lorazepam—GABRA1—Transmission across Chemical Synapses—ADCY7—hematologic cancer	0.000187	0.00288	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—GRB2—hematologic cancer	0.000185	0.00284	CbGpPWpGaD
Lorazepam—Dizziness—Thalidomide—hematologic cancer	0.000182	0.000197	CcSEcCtD
Lorazepam—GABRB3—Neuronal System—SLC22A1—hematologic cancer	0.000182	0.0028	CbGpPWpGaD
Lorazepam—Somnolence—Etoposide—hematologic cancer	0.000182	0.000196	CcSEcCtD
Lorazepam—Nausea—Bortezomib—hematologic cancer	0.000182	0.000196	CcSEcCtD
Lorazepam—Hypersensitivity—Mitoxantrone—hematologic cancer	0.000181	0.000196	CcSEcCtD
Lorazepam—Hypersensitivity—Irinotecan—hematologic cancer	0.000181	0.000196	CcSEcCtD
Lorazepam—Asthenia—Vincristine—hematologic cancer	0.000181	0.000196	CcSEcCtD
Lorazepam—Tachycardia—Triamcinolone—hematologic cancer	0.000181	0.000196	CcSEcCtD
Lorazepam—Vomiting—Thiotepa—hematologic cancer	0.000181	0.000195	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—MTAP—hematologic cancer	0.000181	0.00278	CbGpPWpGaD
Lorazepam—Nausea—Bleomycin—hematologic cancer	0.00018	0.000194	CcSEcCtD
Lorazepam—Drowsiness—Epirubicin—hematologic cancer	0.00018	0.000194	CcSEcCtD
Lorazepam—Erythema—Prednisone—hematologic cancer	0.00018	0.000194	CcSEcCtD
Lorazepam—Rash—Thiotepa—hematologic cancer	0.00018	0.000194	CcSEcCtD
Lorazepam—Dermatitis—Thiotepa—hematologic cancer	0.00018	0.000194	CcSEcCtD
Lorazepam—Agranulocytosis—Methotrexate—hematologic cancer	0.00018	0.000194	CcSEcCtD
Lorazepam—Chlorprothixene—ABCB1—hematologic cancer	0.000179	0.0237	CrCbGaD
Lorazepam—Convulsion—Dexamethasone—hematologic cancer	0.000179	0.000193	CcSEcCtD
Lorazepam—Convulsion—Betamethasone—hematologic cancer	0.000179	0.000193	CcSEcCtD
Lorazepam—GABRG2—Neuronal System—SLC22A1—hematologic cancer	0.000179	0.00275	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.000179	0.00275	CbGpPWpGaD
Lorazepam—Headache—Thiotepa—hematologic cancer	0.000179	0.000193	CcSEcCtD
Lorazepam—Hypertension—Betamethasone—hematologic cancer	0.000178	0.000192	CcSEcCtD
Lorazepam—Hypertension—Dexamethasone—hematologic cancer	0.000178	0.000192	CcSEcCtD
Lorazepam—GABRB3—BDNF signaling pathway—STAT5A—hematologic cancer	0.000178	0.00273	CbGpPWpGaD
Lorazepam—Pancytopenia—Doxorubicin—hematologic cancer	0.000177	0.000191	CcSEcCtD
Lorazepam—Nausea—Vinorelbine—hematologic cancer	0.000177	0.000191	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Etoposide—hematologic cancer	0.000177	0.000191	CcSEcCtD
Lorazepam—Asthenia—Irinotecan—hematologic cancer	0.000177	0.000191	CcSEcCtD
Lorazepam—Asthenia—Mitoxantrone—hematologic cancer	0.000177	0.000191	CcSEcCtD
Lorazepam—Fatigue—Etoposide—hematologic cancer	0.000177	0.00019	CcSEcCtD
Lorazepam—GABRG2—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.000176	0.0027	CbGpPWpGaD
Lorazepam—Jaundice—Epirubicin—hematologic cancer	0.000175	0.000189	CcSEcCtD
Lorazepam—Vomiting—Thalidomide—hematologic cancer	0.000175	0.000189	CcSEcCtD
Lorazepam—Dizziness—Carmustine—hematologic cancer	0.000175	0.000189	CcSEcCtD
Lorazepam—Constipation—Etoposide—hematologic cancer	0.000175	0.000189	CcSEcCtD
Lorazepam—Pain—Etoposide—hematologic cancer	0.000175	0.000189	CcSEcCtD
Lorazepam—Rash—Thalidomide—hematologic cancer	0.000174	0.000188	CcSEcCtD
Lorazepam—Dermatitis—Thalidomide—hematologic cancer	0.000174	0.000187	CcSEcCtD
Lorazepam—Dizziness—Alitretinoin—hematologic cancer	0.000174	0.000187	CcSEcCtD
Lorazepam—Headache—Thalidomide—hematologic cancer	0.000173	0.000186	CcSEcCtD
Lorazepam—Pain—Prednisolone—hematologic cancer	0.000173	0.000186	CcSEcCtD
Lorazepam—Asthenia—Gemcitabine—hematologic cancer	0.000172	0.000186	CcSEcCtD
Lorazepam—Dizziness—Ifosfamide—hematologic cancer	0.000172	0.000185	CcSEcCtD
Lorazepam—Vision blurred—Prednisone—hematologic cancer	0.00017	0.000183	CcSEcCtD
Lorazepam—Nausea—Thiotepa—hematologic cancer	0.000169	0.000183	CcSEcCtD
Lorazepam—Feeling abnormal—Etoposide—hematologic cancer	0.000169	0.000182	CcSEcCtD
Lorazepam—Vomiting—Carmustine—hematologic cancer	0.000168	0.000182	CcSEcCtD
Lorazepam—Agranulocytosis—Epirubicin—hematologic cancer	0.000168	0.000181	CcSEcCtD
Lorazepam—Infection—Betamethasone—hematologic cancer	0.000167	0.000181	CcSEcCtD
Lorazepam—Infection—Dexamethasone—hematologic cancer	0.000167	0.000181	CcSEcCtD
Lorazepam—Flurazepam—ABCB1—hematologic cancer	0.000167	0.0221	CrCbGaD
Lorazepam—Dizziness—Vincristine—hematologic cancer	0.000167	0.00018	CcSEcCtD
Lorazepam—Rash—Carmustine—hematologic cancer	0.000167	0.00018	CcSEcCtD
Lorazepam—GABRB3—Neuronal System—ADCY7—hematologic cancer	0.000167	0.00257	CbGpPWpGaD
Lorazepam—Dermatitis—Carmustine—hematologic cancer	0.000167	0.00018	CcSEcCtD
Lorazepam—Vomiting—Alitretinoin—hematologic cancer	0.000167	0.00018	CcSEcCtD
Lorazepam—Drowsiness—Doxorubicin—hematologic cancer	0.000167	0.00018	CcSEcCtD
Lorazepam—Feeling abnormal—Prednisolone—hematologic cancer	0.000166	0.00018	CcSEcCtD
Lorazepam—Visual impairment—Methotrexate—hematologic cancer	0.000166	0.000179	CcSEcCtD
Lorazepam—GABRA1—Transmission across Chemical Synapses—CAMK2D—hematologic cancer	0.000166	0.00256	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.000166	0.00256	CbGpPWpGaD
Lorazepam—Headache—Carmustine—hematologic cancer	0.000166	0.000179	CcSEcCtD
Lorazepam—Rash—Alitretinoin—hematologic cancer	0.000165	0.000178	CcSEcCtD
Lorazepam—Agitation—Prednisone—hematologic cancer	0.000165	0.000178	CcSEcCtD
Lorazepam—Dermatitis—Alitretinoin—hematologic cancer	0.000165	0.000178	CcSEcCtD
Lorazepam—Thrombocytopenia—Dexamethasone—hematologic cancer	0.000165	0.000178	CcSEcCtD
Lorazepam—Thrombocytopenia—Betamethasone—hematologic cancer	0.000165	0.000178	CcSEcCtD
Lorazepam—Vomiting—Ifosfamide—hematologic cancer	0.000165	0.000178	CcSEcCtD
Lorazepam—Hypersensitivity—Cisplatin—hematologic cancer	0.000165	0.000178	CcSEcCtD
Lorazepam—Tachycardia—Dexamethasone—hematologic cancer	0.000165	0.000177	CcSEcCtD
Lorazepam—Tachycardia—Betamethasone—hematologic cancer	0.000165	0.000177	CcSEcCtD
Lorazepam—Bradycardia—Epirubicin—hematologic cancer	0.000165	0.000177	CcSEcCtD
Lorazepam—Headache—Alitretinoin—hematologic cancer	0.000164	0.000177	CcSEcCtD
Lorazepam—GABRG2—Neuronal System—ADCY7—hematologic cancer	0.000164	0.00252	CbGpPWpGaD
Lorazepam—Nausea—Thalidomide—hematologic cancer	0.000164	0.000177	CcSEcCtD
Lorazepam—Rash—Ifosfamide—hematologic cancer	0.000164	0.000176	CcSEcCtD
Lorazepam—Dermatitis—Ifosfamide—hematologic cancer	0.000163	0.000176	CcSEcCtD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.000163	0.00251	CbGpPWpGaD
Lorazepam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCG—hematologic cancer	0.000163	0.00251	CbGpPWpGaD
Lorazepam—Dizziness—Irinotecan—hematologic cancer	0.000163	0.000176	CcSEcCtD
Lorazepam—Jaundice—Doxorubicin—hematologic cancer	0.000162	0.000175	CcSEcCtD
Lorazepam—Vertigo—Prednisone—hematologic cancer	0.000162	0.000174	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—FHL2—hematologic cancer	0.000161	0.00248	CbGpPWpGaD
Lorazepam—Vomiting—Vincristine—hematologic cancer	0.000161	0.000173	CcSEcCtD
Lorazepam—Asthenia—Cisplatin—hematologic cancer	0.00016	0.000173	CcSEcCtD
Lorazepam—Fatigue—Triamcinolone—hematologic cancer	0.00016	0.000173	CcSEcCtD
Lorazepam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCG—hematologic cancer	0.00016	0.00246	CbGpPWpGaD
Lorazepam—Rash—Vincristine—hematologic cancer	0.000159	0.000172	CcSEcCtD
Lorazepam—Dermatitis—Vincristine—hematologic cancer	0.000159	0.000172	CcSEcCtD
Lorazepam—Pain—Triamcinolone—hematologic cancer	0.000159	0.000171	CcSEcCtD
Lorazepam—Headache—Vincristine—hematologic cancer	0.000158	0.000171	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—AGRN—hematologic cancer	0.000158	0.00243	CbGpPWpGaD
Lorazepam—Hypotension—Betamethasone—hematologic cancer	0.000158	0.00017	CcSEcCtD
Lorazepam—Hypotension—Dexamethasone—hematologic cancer	0.000158	0.00017	CcSEcCtD
Lorazepam—Nausea—Carmustine—hematologic cancer	0.000157	0.00017	CcSEcCtD
Lorazepam—Vomiting—Irinotecan—hematologic cancer	0.000157	0.000169	CcSEcCtD
Lorazepam—Vomiting—Mitoxantrone—hematologic cancer	0.000157	0.000169	CcSEcCtD
Lorazepam—GABRA1—Neuronal System—SLC22A1—hematologic cancer	0.000156	0.00241	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	0.000156	0.00241	CbGpPWpGaD
Lorazepam—Nausea—Alitretinoin—hematologic cancer	0.000156	0.000168	CcSEcCtD
Lorazepam—Convulsion—Prednisone—hematologic cancer	0.000156	0.000168	CcSEcCtD
Lorazepam—Visual impairment—Epirubicin—hematologic cancer	0.000156	0.000168	CcSEcCtD
Lorazepam—Agranulocytosis—Doxorubicin—hematologic cancer	0.000155	0.000168	CcSEcCtD
Lorazepam—Hypertension—Prednisone—hematologic cancer	0.000155	0.000167	CcSEcCtD
Lorazepam—Rash—Mitoxantrone—hematologic cancer	0.000155	0.000167	CcSEcCtD
Lorazepam—Rash—Irinotecan—hematologic cancer	0.000155	0.000167	CcSEcCtD
Lorazepam—Midazolam—ABCB1—hematologic cancer	0.000155	0.0205	CrCbGaD
Lorazepam—Dermatitis—Irinotecan—hematologic cancer	0.000155	0.000167	CcSEcCtD
Lorazepam—Dermatitis—Mitoxantrone—hematologic cancer	0.000155	0.000167	CcSEcCtD
Lorazepam—Chills—Methotrexate—hematologic cancer	0.000155	0.000167	CcSEcCtD
Lorazepam—Headache—Mitoxantrone—hematologic cancer	0.000154	0.000166	CcSEcCtD
Lorazepam—Headache—Irinotecan—hematologic cancer	0.000154	0.000166	CcSEcCtD
Lorazepam—Nausea—Ifosfamide—hematologic cancer	0.000154	0.000166	CcSEcCtD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—AR—hematologic cancer	0.000154	0.00237	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	0.000153	0.00236	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.000153	0.00236	CbGpPWpGaD
Lorazepam—Feeling abnormal—Triamcinolone—hematologic cancer	0.000153	0.000165	CcSEcCtD
Lorazepam—Alopecia—Methotrexate—hematologic cancer	0.000153	0.000165	CcSEcCtD
Lorazepam—Vomiting—Gemcitabine—hematologic cancer	0.000153	0.000164	CcSEcCtD
Lorazepam—Bradycardia—Doxorubicin—hematologic cancer	0.000152	0.000164	CcSEcCtD
Lorazepam—Rash—Gemcitabine—hematologic cancer	0.000151	0.000163	CcSEcCtD
Lorazepam—Dermatitis—Gemcitabine—hematologic cancer	0.000151	0.000163	CcSEcCtD
Lorazepam—Hypersensitivity—Etoposide—hematologic cancer	0.000151	0.000163	CcSEcCtD
Lorazepam—Erythema—Methotrexate—hematologic cancer	0.00015	0.000162	CcSEcCtD
Lorazepam—Headache—Gemcitabine—hematologic cancer	0.00015	0.000162	CcSEcCtD
Lorazepam—Nausea—Vincristine—hematologic cancer	0.00015	0.000162	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—HMMR—hematologic cancer	0.00015	0.0023	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—IDH2—hematologic cancer	0.00015	0.0023	CbGpPWpGaD
Lorazepam—GABRB3—Orphan transporters—CREBBP—hematologic cancer	0.000149	0.0023	CbGpPWpGaD
Lorazepam—Hypersensitivity—Prednisolone—hematologic cancer	0.000149	0.00016	CcSEcCtD
Lorazepam—GABRB3—Neuronal System—CAMK2D—hematologic cancer	0.000149	0.00229	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	0.000148	0.00228	CbGpPWpGaD
Lorazepam—Asthenia—Etoposide—hematologic cancer	0.000147	0.000158	CcSEcCtD
Lorazepam—GABRG2—Orphan transporters—CREBBP—hematologic cancer	0.000146	0.00225	CbGpPWpGaD
Lorazepam—Nausea—Mitoxantrone—hematologic cancer	0.000146	0.000158	CcSEcCtD
Lorazepam—Nausea—Irinotecan—hematologic cancer	0.000146	0.000158	CcSEcCtD
Lorazepam—Infection—Prednisone—hematologic cancer	0.000146	0.000157	CcSEcCtD
Lorazepam—GABRG2—Neuronal System—CAMK2D—hematologic cancer	0.000146	0.00224	CbGpPWpGaD
Lorazepam—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000146	0.000157	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000146	0.000157	CcSEcCtD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	0.000145	0.00224	CbGpPWpGaD
Lorazepam—Fatigue—Betamethasone—hematologic cancer	0.000145	0.000157	CcSEcCtD
Lorazepam—Fatigue—Dexamethasone—hematologic cancer	0.000145	0.000157	CcSEcCtD
Lorazepam—Chills—Epirubicin—hematologic cancer	0.000145	0.000156	CcSEcCtD
Lorazepam—Arrhythmia—Epirubicin—hematologic cancer	0.000144	0.000156	CcSEcCtD
Lorazepam—Pain—Dexamethasone—hematologic cancer	0.000144	0.000155	CcSEcCtD
Lorazepam—Pain—Betamethasone—hematologic cancer	0.000144	0.000155	CcSEcCtD
Lorazepam—Visual impairment—Doxorubicin—hematologic cancer	0.000144	0.000155	CcSEcCtD
Lorazepam—Tachycardia—Prednisone—hematologic cancer	0.000143	0.000154	CcSEcCtD
Lorazepam—GABRA1—Neuronal System—ADCY7—hematologic cancer	0.000143	0.00221	CbGpPWpGaD
Lorazepam—Alopecia—Epirubicin—hematologic cancer	0.000143	0.000154	CcSEcCtD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.000143	0.0022	CbGpPWpGaD
Lorazepam—Nausea—Gemcitabine—hematologic cancer	0.000142	0.000154	CcSEcCtD
Lorazepam—Vomiting—Cisplatin—hematologic cancer	0.000142	0.000153	CcSEcCtD
Lorazepam—Vision blurred—Methotrexate—hematologic cancer	0.000142	0.000153	CcSEcCtD
Lorazepam—Rash—Cisplatin—hematologic cancer	0.000141	0.000152	CcSEcCtD
Lorazepam—Dermatitis—Cisplatin—hematologic cancer	0.000141	0.000152	CcSEcCtD
Lorazepam—Erythema—Epirubicin—hematologic cancer	0.000141	0.000152	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—ARNTL—hematologic cancer	0.000141	0.00216	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—TSC2—hematologic cancer	0.00014	0.00216	CbGpPWpGaD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCG—hematologic cancer	0.00014	0.00215	CbGpPWpGaD
Lorazepam—Diazepam—ALB—hematologic cancer	0.000139	0.0184	CrCbGaD
Lorazepam—Feeling abnormal—Dexamethasone—hematologic cancer	0.000139	0.00015	CcSEcCtD
Lorazepam—Feeling abnormal—Betamethasone—hematologic cancer	0.000139	0.00015	CcSEcCtD
Lorazepam—Tension—Epirubicin—hematologic cancer	0.000138	0.000149	CcSEcCtD
Lorazepam—Hypersensitivity—Triamcinolone—hematologic cancer	0.000137	0.000148	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—CA9—hematologic cancer	0.000137	0.00211	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ACP5—hematologic cancer	0.000137	0.00211	CbGpPWpGaD
Lorazepam—Nervousness—Epirubicin—hematologic cancer	0.000137	0.000147	CcSEcCtD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ANXA2—hematologic cancer	0.000135	0.00209	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SGK1—hematologic cancer	0.000135	0.00209	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ATP4A—hematologic cancer	0.000135	0.00209	CbGpPWpGaD
Lorazepam—Dizziness—Etoposide—hematologic cancer	0.000135	0.000146	CcSEcCtD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—HES1—hematologic cancer	0.000135	0.00208	CbGpPWpGaD
Lorazepam—Vertigo—Methotrexate—hematologic cancer	0.000135	0.000146	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—NCOR2—hematologic cancer	0.000135	0.00208	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—IL10—hematologic cancer	0.000134	0.00207	CbGpPWpGaD
Lorazepam—Chills—Doxorubicin—hematologic cancer	0.000134	0.000145	CcSEcCtD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	0.000134	0.00206	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—MAPK14—hematologic cancer	0.000134	0.00206	CbGpPWpGaD
Lorazepam—Dizziness—Prednisolone—hematologic cancer	0.000134	0.000144	CcSEcCtD
Lorazepam—Arrhythmia—Doxorubicin—hematologic cancer	0.000134	0.000144	CcSEcCtD
Lorazepam—Asthenia—Triamcinolone—hematologic cancer	0.000133	0.000144	CcSEcCtD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ANXA2—hematologic cancer	0.000133	0.00205	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ATP4A—hematologic cancer	0.000133	0.00205	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SGK1—hematologic cancer	0.000133	0.00205	CbGpPWpGaD
Lorazepam—Diazepam—ABCB1—hematologic cancer	0.000133	0.0176	CrCbGaD
Lorazepam—Nausea—Cisplatin—hematologic cancer	0.000133	0.000143	CcSEcCtD
Lorazepam—Vision blurred—Epirubicin—hematologic cancer	0.000133	0.000143	CcSEcCtD
Lorazepam—Alopecia—Doxorubicin—hematologic cancer	0.000132	0.000142	CcSEcCtD
Lorazepam—Clozapine—ABCB1—hematologic cancer	0.000131	0.0173	CrCbGaD
Lorazepam—Convulsion—Methotrexate—hematologic cancer	0.00013	0.00014	CcSEcCtD
Lorazepam—Vomiting—Etoposide—hematologic cancer	0.00013	0.00014	CcSEcCtD
Lorazepam—Erythema—Doxorubicin—hematologic cancer	0.00013	0.00014	CcSEcCtD
Lorazepam—Agitation—Epirubicin—hematologic cancer	0.000129	0.000139	CcSEcCtD
Lorazepam—Rash—Etoposide—hematologic cancer	0.000129	0.000139	CcSEcCtD
Lorazepam—Dermatitis—Etoposide—hematologic cancer	0.000129	0.000139	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—IDH1—hematologic cancer	0.000129	0.00198	CbGpPWpGaD
Lorazepam—Headache—Etoposide—hematologic cancer	0.000128	0.000138	CcSEcCtD
Lorazepam—GABRB3—BDNF signaling pathway—NFKBIA—hematologic cancer	0.000128	0.00197	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—BAD—hematologic cancer	0.000128	0.00197	CbGpPWpGaD
Lorazepam—GABRA1—Orphan transporters—CREBBP—hematologic cancer	0.000128	0.00197	CbGpPWpGaD
Lorazepam—Tension—Doxorubicin—hematologic cancer	0.000128	0.000138	CcSEcCtD
Lorazepam—GABRA1—Neuronal System—CAMK2D—hematologic cancer	0.000127	0.00196	CbGpPWpGaD
Lorazepam—Rash—Prednisolone—hematologic cancer	0.000127	0.000137	CcSEcCtD
Lorazepam—Dermatitis—Prednisolone—hematologic cancer	0.000127	0.000137	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—ABCC3—hematologic cancer	0.000127	0.00196	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—TXN—hematologic cancer	0.000127	0.00196	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTO1—hematologic cancer	0.000127	0.00196	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	0.000127	0.00196	CbGpPWpGaD
Lorazepam—Fatigue—Prednisone—hematologic cancer	0.000127	0.000136	CcSEcCtD
Lorazepam—Headache—Prednisolone—hematologic cancer	0.000127	0.000136	CcSEcCtD
Lorazepam—Nervousness—Doxorubicin—hematologic cancer	0.000126	0.000136	CcSEcCtD
Lorazepam—Vertigo—Epirubicin—hematologic cancer	0.000126	0.000136	CcSEcCtD
Lorazepam—Constipation—Prednisone—hematologic cancer	0.000126	0.000135	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—SPHK1—hematologic cancer	0.000124	0.00192	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—NR3C1—hematologic cancer	0.000124	0.00191	CbGpPWpGaD
Lorazepam—Confusional state—Methotrexate—hematologic cancer	0.000124	0.000133	CcSEcCtD
Lorazepam—Dizziness—Triamcinolone—hematologic cancer	0.000123	0.000132	CcSEcCtD
Lorazepam—Vision blurred—Doxorubicin—hematologic cancer	0.000123	0.000132	CcSEcCtD
Lorazepam—GABRB3—Transmission across Chemical Synapses—PRKCG—hematologic cancer	0.000123	0.00189	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	0.000122	0.00188	CbGpPWpGaD
Lorazepam—Convulsion—Epirubicin—hematologic cancer	0.000122	0.000131	CcSEcCtD
Lorazepam—Infection—Methotrexate—hematologic cancer	0.000122	0.000131	CcSEcCtD
Lorazepam—GABRB3—BDNF signaling pathway—PTPN11—hematologic cancer	0.000122	0.00188	CbGpPWpGaD
Lorazepam—Nausea—Etoposide—hematologic cancer	0.000122	0.000131	CcSEcCtD
Lorazepam—Hypertension—Epirubicin—hematologic cancer	0.000121	0.000131	CcSEcCtD
Lorazepam—Feeling abnormal—Prednisone—hematologic cancer	0.000121	0.00013	CcSEcCtD
Lorazepam—Asthenia—Betamethasone—hematologic cancer	0.000121	0.00013	CcSEcCtD
Lorazepam—Asthenia—Dexamethasone—hematologic cancer	0.000121	0.00013	CcSEcCtD
Lorazepam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—hematologic cancer	0.000121	0.00186	CbGpPWpGaD
Lorazepam—GABRG2—Transmission across Chemical Synapses—PRKCG—hematologic cancer	0.00012	0.00185	CbGpPWpGaD
Lorazepam—Thrombocytopenia—Methotrexate—hematologic cancer	0.00012	0.00013	CcSEcCtD
Lorazepam—Nausea—Prednisolone—hematologic cancer	0.00012	0.000129	CcSEcCtD
Lorazepam—GABRG2—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	0.00012	0.00184	CbGpPWpGaD
Lorazepam—Agitation—Doxorubicin—hematologic cancer	0.00012	0.000129	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—UGT1A1—hematologic cancer	0.00012	0.00184	CbGpPWpGaD
Lorazepam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—hematologic cancer	0.000119	0.00183	CbGpPWpGaD
Lorazepam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—hematologic cancer	0.000119	0.00182	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—FOS—hematologic cancer	0.000118	0.00182	CbGpPWpGaD
Lorazepam—Vomiting—Triamcinolone—hematologic cancer	0.000118	0.000127	CcSEcCtD
Lorazepam—GABRB3—BDNF signaling pathway—CREB1—hematologic cancer	0.000118	0.00182	CbGpPWpGaD
Lorazepam—Rash—Triamcinolone—hematologic cancer	0.000117	0.000126	CcSEcCtD
Lorazepam—Dry mouth—Epirubicin—hematologic cancer	0.000117	0.000126	CcSEcCtD
Lorazepam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—hematologic cancer	0.000117	0.0018	CbGpPWpGaD
Lorazepam—Dermatitis—Triamcinolone—hematologic cancer	0.000117	0.000126	CcSEcCtD
Lorazepam—Vertigo—Doxorubicin—hematologic cancer	0.000117	0.000126	CcSEcCtD
Lorazepam—Headache—Triamcinolone—hematologic cancer	0.000116	0.000126	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—SLC22A1—hematologic cancer	0.000116	0.00179	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CRABP1—hematologic cancer	0.000116	0.00179	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ATP4A—hematologic cancer	0.000116	0.00179	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ANXA2—hematologic cancer	0.000116	0.00179	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SGK1—hematologic cancer	0.000116	0.00179	CbGpPWpGaD
Lorazepam—Confusional state—Epirubicin—hematologic cancer	0.000116	0.000125	CcSEcCtD
Lorazepam—Hypotension—Methotrexate—hematologic cancer	0.000115	0.000124	CcSEcCtD
Lorazepam—Infection—Epirubicin—hematologic cancer	0.000114	0.000123	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—ALOX5—hematologic cancer	0.000113	0.00175	CbGpPWpGaD
Lorazepam—Convulsion—Doxorubicin—hematologic cancer	0.000113	0.000122	CcSEcCtD
Lorazepam—Thrombocytopenia—Epirubicin—hematologic cancer	0.000112	0.000121	CcSEcCtD
Lorazepam—Hypertension—Doxorubicin—hematologic cancer	0.000112	0.000121	CcSEcCtD
Lorazepam—Tachycardia—Epirubicin—hematologic cancer	0.000112	0.000121	CcSEcCtD
Lorazepam—Dizziness—Dexamethasone—hematologic cancer	0.000111	0.00012	CcSEcCtD
Lorazepam—Dizziness—Betamethasone—hematologic cancer	0.000111	0.00012	CcSEcCtD
Lorazepam—Nausea—Triamcinolone—hematologic cancer	0.00011	0.000119	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—NUP98—hematologic cancer	0.00011	0.00169	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—MAP2K1—hematologic cancer	0.00011	0.00169	CbGpPWpGaD
Lorazepam—Somnolence—Methotrexate—hematologic cancer	0.000109	0.000118	CcSEcCtD
Lorazepam—Dry mouth—Doxorubicin—hematologic cancer	0.000108	0.000117	CcSEcCtD
Lorazepam—Hypersensitivity—Prednisone—hematologic cancer	0.000108	0.000117	CcSEcCtD
Lorazepam—Hypotension—Epirubicin—hematologic cancer	0.000107	0.000116	CcSEcCtD
Lorazepam—Vomiting—Betamethasone—hematologic cancer	0.000107	0.000116	CcSEcCtD
Lorazepam—Vomiting—Dexamethasone—hematologic cancer	0.000107	0.000116	CcSEcCtD
Lorazepam—Confusional state—Doxorubicin—hematologic cancer	0.000107	0.000116	CcSEcCtD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ABCC3—hematologic cancer	0.000107	0.00165	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ADCY7—hematologic cancer	0.000107	0.00164	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—NCOA3—hematologic cancer	0.000107	0.00164	CbGpPWpGaD
Lorazepam—Rash—Dexamethasone—hematologic cancer	0.000106	0.000115	CcSEcCtD
Lorazepam—Rash—Betamethasone—hematologic cancer	0.000106	0.000115	CcSEcCtD
Lorazepam—Dermatitis—Dexamethasone—hematologic cancer	0.000106	0.000115	CcSEcCtD
Lorazepam—Dermatitis—Betamethasone—hematologic cancer	0.000106	0.000115	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Methotrexate—hematologic cancer	0.000106	0.000114	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—NUP214—hematologic cancer	0.000106	0.00163	CbGpPWpGaD
Lorazepam—Fatigue—Methotrexate—hematologic cancer	0.000106	0.000114	CcSEcCtD
Lorazepam—Headache—Dexamethasone—hematologic cancer	0.000106	0.000114	CcSEcCtD
Lorazepam—Headache—Betamethasone—hematologic cancer	0.000106	0.000114	CcSEcCtD
Lorazepam—Infection—Doxorubicin—hematologic cancer	0.000106	0.000114	CcSEcCtD
Lorazepam—Asthenia—Prednisone—hematologic cancer	0.000105	0.000114	CcSEcCtD
Lorazepam—GABRA1—Transmission across Chemical Synapses—PRKCG—hematologic cancer	0.000105	0.00162	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ABCC3—hematologic cancer	0.000105	0.00162	CbGpPWpGaD
Lorazepam—Pain—Methotrexate—hematologic cancer	0.000105	0.000113	CcSEcCtD
Lorazepam—GABRA1—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	0.000105	0.00161	CbGpPWpGaD
Lorazepam—Thrombocytopenia—Doxorubicin—hematologic cancer	0.000104	0.000112	CcSEcCtD
Lorazepam—Tachycardia—Doxorubicin—hematologic cancer	0.000104	0.000112	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—MTR—hematologic cancer	0.000104	0.0016	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ABCG2—hematologic cancer	0.000104	0.0016	CbGpPWpGaD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—hematologic cancer	0.000104	0.00159	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—PIK3R1—hematologic cancer	0.000103	0.00158	CbGpPWpGaD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—hematologic cancer	0.000102	0.00158	CbGpPWpGaD
Lorazepam—Somnolence—Epirubicin—hematologic cancer	0.000102	0.00011	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—ENO2—hematologic cancer	0.000102	0.00157	CbGpPWpGaD
Lorazepam—Feeling abnormal—Methotrexate—hematologic cancer	0.000101	0.000109	CcSEcCtD
Lorazepam—Nausea—Betamethasone—hematologic cancer	0.0001	0.000108	CcSEcCtD
Lorazepam—Nausea—Dexamethasone—hematologic cancer	0.0001	0.000108	CcSEcCtD
Lorazepam—GABRB3—BDNF signaling pathway—JAK2—hematologic cancer	0.0001	0.00154	CbGpPWpGaD
Lorazepam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—hematologic cancer	9.99e-05	0.00154	CbGpPWpGaD
Lorazepam—Hypotension—Doxorubicin—hematologic cancer	9.93e-05	0.000107	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Epirubicin—hematologic cancer	9.91e-05	0.000107	CcSEcCtD
Lorazepam—Fatigue—Epirubicin—hematologic cancer	9.9e-05	0.000107	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—GSTT1—hematologic cancer	9.86e-05	0.00152	CbGpPWpGaD
Lorazepam—Pain—Epirubicin—hematologic cancer	9.82e-05	0.000106	CcSEcCtD
Lorazepam—Constipation—Epirubicin—hematologic cancer	9.82e-05	0.000106	CcSEcCtD
Lorazepam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—hematologic cancer	9.81e-05	0.00151	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	9.8e-05	0.00151	CbGpPWpGaD
Lorazepam—Dizziness—Prednisone—hematologic cancer	9.71e-05	0.000105	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—SDC1—hematologic cancer	9.64e-05	0.00148	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	9.62e-05	0.00148	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—CREB1—hematologic cancer	9.5e-05	0.00146	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—MTOR—hematologic cancer	9.5e-05	0.00146	CbGpPWpGaD
Lorazepam—Feeling abnormal—Epirubicin—hematologic cancer	9.46e-05	0.000102	CcSEcCtD
Lorazepam—Somnolence—Doxorubicin—hematologic cancer	9.45e-05	0.000102	CcSEcCtD
Lorazepam—GABRB3—Neuronal System—PRKCG—hematologic cancer	9.39e-05	0.00145	CbGpPWpGaD
Lorazepam—Vomiting—Prednisone—hematologic cancer	9.33e-05	0.000101	CcSEcCtD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—IL6R—hematologic cancer	9.27e-05	0.00143	CbGpPWpGaD
Lorazepam—Rash—Prednisone—hematologic cancer	9.26e-05	9.98e-05	CcSEcCtD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—CREBBP—hematologic cancer	9.26e-05	0.00142	CbGpPWpGaD
Lorazepam—Dermatitis—Prednisone—hematologic cancer	9.25e-05	9.97e-05	CcSEcCtD
Lorazepam—GABRB3—Transmembrane transport of small molecules—NUP98—hematologic cancer	9.24e-05	0.00142	CbGpPWpGaD
Lorazepam—GABRG2—Neuronal System—PRKCG—hematologic cancer	9.22e-05	0.00142	CbGpPWpGaD
Lorazepam—Headache—Prednisone—hematologic cancer	9.2e-05	9.92e-05	CcSEcCtD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ABCC3—hematologic cancer	9.19e-05	0.00141	CbGpPWpGaD
Lorazepam—Gastrointestinal disorder—Doxorubicin—hematologic cancer	9.17e-05	9.89e-05	CcSEcCtD
Lorazepam—Fatigue—Doxorubicin—hematologic cancer	9.16e-05	9.88e-05	CcSEcCtD
Lorazepam—Pain—Doxorubicin—hematologic cancer	9.09e-05	9.8e-05	CcSEcCtD
Lorazepam—Constipation—Doxorubicin—hematologic cancer	9.09e-05	9.8e-05	CcSEcCtD
Lorazepam—GABRG2—Transmembrane transport of small molecules—NUP98—hematologic cancer	9.08e-05	0.0014	CbGpPWpGaD
Lorazepam—GABRB3—Transmission across Chemical Synapses—CREB1—hematologic cancer	9.08e-05	0.0014	CbGpPWpGaD
Lorazepam—Hypersensitivity—Methotrexate—hematologic cancer	9.04e-05	9.75e-05	CcSEcCtD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ADCY7—hematologic cancer	8.97e-05	0.00138	CbGpPWpGaD
Lorazepam—GABRB3—Transmission across Chemical Synapses—BRAF—hematologic cancer	8.96e-05	0.00138	CbGpPWpGaD
Lorazepam—GABRG2—Transmission across Chemical Synapses—CREB1—hematologic cancer	8.91e-05	0.00137	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—NUP214—hematologic cancer	8.91e-05	0.00137	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ADCY7—hematologic cancer	8.81e-05	0.00136	CbGpPWpGaD
Lorazepam—Asthenia—Methotrexate—hematologic cancer	8.8e-05	9.49e-05	CcSEcCtD
Lorazepam—GABRG2—Transmission across Chemical Synapses—BRAF—hematologic cancer	8.8e-05	0.00135	CbGpPWpGaD
Lorazepam—Feeling abnormal—Doxorubicin—hematologic cancer	8.76e-05	9.44e-05	CcSEcCtD
Lorazepam—GABRG2—Transmembrane transport of small molecules—NUP214—hematologic cancer	8.75e-05	0.00135	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—CASP3—hematologic cancer	8.74e-05	0.00135	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ABCG2—hematologic cancer	8.73e-05	0.00134	CbGpPWpGaD
Lorazepam—Nausea—Prednisone—hematologic cancer	8.72e-05	9.4e-05	CcSEcCtD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ABCG2—hematologic cancer	8.57e-05	0.00132	CbGpPWpGaD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—hematologic cancer	8.57e-05	0.00132	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—JUN—hematologic cancer	8.49e-05	0.00131	CbGpPWpGaD
Lorazepam—Hypersensitivity—Epirubicin—hematologic cancer	8.46e-05	9.12e-05	CcSEcCtD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	8.41e-05	0.00129	CbGpPWpGaD
Lorazepam—Asthenia—Epirubicin—hematologic cancer	8.24e-05	8.88e-05	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—NQO1—hematologic cancer	8.2e-05	0.00126	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CD44—hematologic cancer	8.2e-05	0.00126	CbGpPWpGaD
Lorazepam—Dizziness—Methotrexate—hematologic cancer	8.11e-05	8.75e-05	CcSEcCtD
Lorazepam—GABRA1—Neuronal System—PRKCG—hematologic cancer	8.06e-05	0.00124	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—MAPK8—hematologic cancer	8.03e-05	0.00124	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—NUP98—hematologic cancer	7.94e-05	0.00122	CbGpPWpGaD
Lorazepam—Hypersensitivity—Doxorubicin—hematologic cancer	7.83e-05	8.44e-05	CcSEcCtD
Lorazepam—Vomiting—Methotrexate—hematologic cancer	7.8e-05	8.41e-05	CcSEcCtD
Lorazepam—GABRA1—Transmission across Chemical Synapses—CREB1—hematologic cancer	7.79e-05	0.0012	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—TFRC—hematologic cancer	7.78e-05	0.0012	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYCS—hematologic cancer	7.76e-05	0.00119	CbGpPWpGaD
Lorazepam—Rash—Methotrexate—hematologic cancer	7.74e-05	8.34e-05	CcSEcCtD
Lorazepam—Dermatitis—Methotrexate—hematologic cancer	7.73e-05	8.33e-05	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—HSP90AA1—hematologic cancer	7.71e-05	0.00119	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ADCY7—hematologic cancer	7.7e-05	0.00119	CbGpPWpGaD
Lorazepam—GABRA1—Transmission across Chemical Synapses—BRAF—hematologic cancer	7.69e-05	0.00118	CbGpPWpGaD
Lorazepam—Headache—Methotrexate—hematologic cancer	7.69e-05	8.29e-05	CcSEcCtD
Lorazepam—GABRA1—Transmembrane transport of small molecules—NUP214—hematologic cancer	7.65e-05	0.00118	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—TFRC—hematologic cancer	7.64e-05	0.00118	CbGpPWpGaD
Lorazepam—Asthenia—Doxorubicin—hematologic cancer	7.62e-05	8.22e-05	CcSEcCtD
Lorazepam—GABRB3—BDNF signaling pathway—SRC—hematologic cancer	7.61e-05	0.00117	CbGpPWpGaD
Lorazepam—Dizziness—Epirubicin—hematologic cancer	7.59e-05	8.19e-05	CcSEcCtD
Lorazepam—GABRB3—Transmission across Chemical Synapses—MDM2—hematologic cancer	7.51e-05	0.00116	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ABCG2—hematologic cancer	7.49e-05	0.00115	CbGpPWpGaD
Lorazepam—GABRG2—Transmission across Chemical Synapses—MDM2—hematologic cancer	7.37e-05	0.00113	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—STAT3—hematologic cancer	7.34e-05	0.00113	CbGpPWpGaD
Lorazepam—Vomiting—Epirubicin—hematologic cancer	7.3e-05	7.87e-05	CcSEcCtD
Lorazepam—Nausea—Methotrexate—hematologic cancer	7.29e-05	7.86e-05	CcSEcCtD
Lorazepam—Rash—Epirubicin—hematologic cancer	7.24e-05	7.81e-05	CcSEcCtD
Lorazepam—Dermatitis—Epirubicin—hematologic cancer	7.23e-05	7.8e-05	CcSEcCtD
Lorazepam—Headache—Epirubicin—hematologic cancer	7.19e-05	7.76e-05	CcSEcCtD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—IL1B—hematologic cancer	7.05e-05	0.00109	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—CASP3—hematologic cancer	7.04e-05	0.00108	CbGpPWpGaD
Lorazepam—Dizziness—Doxorubicin—hematologic cancer	7.03e-05	7.58e-05	CcSEcCtD
Lorazepam—GABRB3—BDNF signaling pathway—MAPK3—hematologic cancer	7.02e-05	0.00108	CbGpPWpGaD
Lorazepam—GABRB3—Neuronal System—CREB1—hematologic cancer	6.95e-05	0.00107	CbGpPWpGaD
Lorazepam—GABRB3—Neuronal System—BRAF—hematologic cancer	6.87e-05	0.00106	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTP1—hematologic cancer	6.84e-05	0.00105	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—JUN—hematologic cancer	6.83e-05	0.00105	CbGpPWpGaD
Lorazepam—GABRG2—Neuronal System—CREB1—hematologic cancer	6.83e-05	0.00105	CbGpPWpGaD
Lorazepam—Nausea—Epirubicin—hematologic cancer	6.82e-05	7.35e-05	CcSEcCtD
Lorazepam—Vomiting—Doxorubicin—hematologic cancer	6.76e-05	7.28e-05	CcSEcCtD
Lorazepam—GABRG2—Neuronal System—BRAF—hematologic cancer	6.74e-05	0.00104	CbGpPWpGaD
Lorazepam—Rash—Doxorubicin—hematologic cancer	6.7e-05	7.22e-05	CcSEcCtD
Lorazepam—Dermatitis—Doxorubicin—hematologic cancer	6.69e-05	7.22e-05	CcSEcCtD
Lorazepam—GABRA1—Transmembrane transport of small molecules—TFRC—hematologic cancer	6.68e-05	0.00103	CbGpPWpGaD
Lorazepam—Headache—Doxorubicin—hematologic cancer	6.66e-05	7.18e-05	CcSEcCtD
Lorazepam—GABRB3—Transmembrane transport of small molecules—CYCS—hematologic cancer	6.53e-05	0.00101	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ABCB1—hematologic cancer	6.47e-05	0.000996	CbGpPWpGaD
Lorazepam—GABRA1—Transmission across Chemical Synapses—MDM2—hematologic cancer	6.44e-05	0.000992	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—CYCS—hematologic cancer	6.41e-05	0.000987	CbGpPWpGaD
Lorazepam—Nausea—Doxorubicin—hematologic cancer	6.31e-05	6.8e-05	CcSEcCtD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—EP300—hematologic cancer	6.3e-05	0.00097	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTM1—hematologic cancer	6.28e-05	0.000967	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—NCOR1—hematologic cancer	6.28e-05	0.000967	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—VEGFA—hematologic cancer	5.97e-05	0.000919	CbGpPWpGaD
Lorazepam—GABRA1—Neuronal System—CREB1—hematologic cancer	5.97e-05	0.000919	CbGpPWpGaD
Lorazepam—GABRA1—Neuronal System—BRAF—hematologic cancer	5.89e-05	0.000907	CbGpPWpGaD
Lorazepam—GABRB3—Neuronal System—MDM2—hematologic cancer	5.75e-05	0.000886	CbGpPWpGaD
Lorazepam—GABRG2—Neuronal System—MDM2—hematologic cancer	5.65e-05	0.00087	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—CYCS—hematologic cancer	5.61e-05	0.000863	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—MTHFR—hematologic cancer	5.55e-05	0.000855	CbGpPWpGaD
Lorazepam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—hematologic cancer	5.48e-05	0.000844	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ABCB1—hematologic cancer	5.45e-05	0.000839	CbGpPWpGaD
Lorazepam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—hematologic cancer	5.38e-05	0.000828	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—HRAS—hematologic cancer	5.36e-05	0.000825	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ABCB1—hematologic cancer	5.35e-05	0.000824	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—TNF—hematologic cancer	5.12e-05	0.000788	CbGpPWpGaD
Lorazepam—GABRA1—Neuronal System—MDM2—hematologic cancer	4.94e-05	0.00076	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—AKT1—hematologic cancer	4.73e-05	0.000728	CbGpPWpGaD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—hematologic cancer	4.7e-05	0.000724	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ABCB1—hematologic cancer	4.68e-05	0.00072	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PIK3CG—hematologic cancer	4.66e-05	0.000718	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CREBBP—hematologic cancer	4.32e-05	0.000666	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—IL6—hematologic cancer	4.13e-05	0.000636	CbGpPWpGaD
Lorazepam—GABRB3—Transmission across Chemical Synapses—HRAS—hematologic cancer	4.12e-05	0.000634	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PIK3CD—hematologic cancer	4.1e-05	0.000631	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ALB—hematologic cancer	4.05e-05	0.000623	CbGpPWpGaD
Lorazepam—GABRG2—Transmission across Chemical Synapses—HRAS—hematologic cancer	4.05e-05	0.000623	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PIK3R1—hematologic cancer	3.87e-05	0.000596	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—CREBBP—hematologic cancer	3.64e-05	0.000561	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	3.58e-05	0.00055	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PIK3CB—hematologic cancer	3.57e-05	0.00055	CbGpPWpGaD
Lorazepam—GABRA1—Transmission across Chemical Synapses—HRAS—hematologic cancer	3.54e-05	0.000544	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ALB—hematologic cancer	3.41e-05	0.000525	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ALB—hematologic cancer	3.35e-05	0.000515	CbGpPWpGaD
Lorazepam—GABRB3—Neuronal System—HRAS—hematologic cancer	3.16e-05	0.000486	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	3.13e-05	0.000481	CbGpPWpGaD
Lorazepam—GABRG2—Neuronal System—HRAS—hematologic cancer	3.1e-05	0.000477	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PTEN—hematologic cancer	3.09e-05	0.000475	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—EP300—hematologic cancer	2.95e-05	0.000453	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ALB—hematologic cancer	2.93e-05	0.00045	CbGpPWpGaD
Lorazepam—GABRA1—Neuronal System—HRAS—hematologic cancer	2.71e-05	0.000417	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PIK3CA—hematologic cancer	2.18e-05	0.000335	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—AKT1—hematologic cancer	1.78e-05	0.000274	CbGpPWpGaD
